|
M3, Inc. operates a global network of medical professional platforms, including m3.com in Japan, MDLinx in the United States, and Doctors.net.uk in the United Kingdom. The company provides marketing support services for pharmaceutical companies, leveraging its platform to facilitate information distribution and conduct surveys among healthcare professionals. Its business segments include Medical Platform, Evidence Solutions, Career Solutions, Site Solutions, Patient Solutions, and Overseas operations. Key services encompass the development and sale of electronic medical records, clinical research organization (CRO) and site management organization (SMO) support, and talent acquisition services for doctors and pharmacists. The group also manages medical facilities, hospice care, and residential care services, while offering patient support products such as care sets for inpatients and care facility residents. In overseas markets, the company provides digital solutions, physician profile database licensing, and clinical trial support services. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Health Information Services | Homepage corporate.m3.com |
| Sector Healthcare | IR page corporate.m3.com | |
|
Tags
medical platforms, pharmaceutical marketing, electronic medical records, clinical research, healthcare staffing, hospice care, patient support, digital health, m3.com, MDLinx, Doctors.net.uk, m3.com CAREER
|
Press page corporate.m3.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 1.202T |
| Market cap (USD) | $ 7.515B |
| P/E | 25.64 |
| PEG | 524.13 |
| P/BV | 2.70 |
| P/S | 3.32 |
| P/OCF | 18.58 |
| P/FCF | 22.80 |
| Dividend yield | 1.2% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 11.4% |
| ROI | 10.2% |
| ROIC | 10.9% |
| Profit margin | 14.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 0.05% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 42 |
| Quality score | 27.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 351.363B | 284.9B | 238.883B | 230.818B | 208.159B | 169.198B | 130.973B | 113.059B | 94.471B | 78.143B | 64.66B | 51.376B | 36.887B | 26.008B |
| Net profit | 49.1B | 40.484B | 45.271B | 49.028B | 63.845B | 37.822B | 21.635B | 19.577B | 19.684B | 16.004B | 12.508B | 8.861B | 8.318B | 5.599B |
| Free cash flow | 58.332B | 42.752B | 50.729B | 49.536B | 48.891B | 44.638B | 23.949B | 16.404B | — | — | — | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.604K | 1.7K | 2.138K | 3.301K | 4.468K | 7.572K | 3.195K | 1.856K | 4.779K | 2.764K | 1.416K | 1.275K | 1.694K | 909.2 |
| Price performance 12m | -0.06 | -0.2 | -0.35 | -0.26 | -0.41 | 1.37 | 0.72 | -0.61 | 0.73 | 0.95 | 0.11 | -0.25 | 0.86 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | — | 24.9B | 28.3B | 33.6B | 43.7B | 50.9B | 50.5B | 51.9B | 65B | 74.6B |
| ↳ YoY growth | +13.7% | +18.7% | +29.9% | +16.5% | -0.7% | +2.8% | +25.3% | +14.7% | ||
| ↳ 5y CAGR | +15.2% | +12.9% | +14.1% | +11.3% | ||||||
| Borrowings, current (JPY) | — | — | — | — | — | — | 17M | 2.03B | 3.08B | 4.17B |
| Borrowings, non-current (JPY) | — | — | — | — | — | — | 94M | 16.5B | 21.3B | 29B |
| Cash and deposits (JPY) | 20.1B | 23.7B | 27.5B | 47.9B | 89.1B | 104B | 118B | 150B | 135B | 156B |
| Intangible assets (JPY) | — | 12.8B | 12.7B | 20.2B | 23B | 25.1B | 40.7B | 51.6B | 94.9B | 99.2B |
| Right-of-use assets (JPY) | — | — | — | — | — | 7.52B | 9.47B | 12.1B | 25.9B | 25.3B |
| Net debt (borrowings + leases - cash) (JPY) | — | — | — | — | — | — | -118B | -131B | -111B | -123B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 16.6B | 15.9B | 17.7B | 26.8B | 46.6B | 52.1B | 57.1B | 58.3B | 51.7B | 70.3B |
| Purchases of property, plant and equipment (JPY) | — | -1.39B | -677M | -1.85B | -1.23B | -1.71B | -5.91B | -5.41B | -6.29B | -7.68B |
| Purchases of intangible assets (JPY) | — | -463M | -668M | -992M | -759M | -1.51B | -1.67B | -2.17B | -2.7B | -4.25B |
| Change in receivables (cash effect) (JPY) | — | -3.99B | -2.74B | -4.22B | -9.49B | -8.84B | 3.09B | 2.25B | -2.52B | -2.27B |
| Change in payables (cash effect) (JPY) | — | 447M | 304M | 1.11B | 2.24B | 6.57B | 129M | 2.44B | -962M | 2.31B |
| Dividends paid (cash effect) (JPY) | — | -3.24B | -3.35B | -4.53B | -5.77B | -8.14B | -10.9B | -12.9B | -14.3B | -14.3B |
| Share buybacks (cash effect) (JPY) | — | — | -1M | — | — | — | — | — | 0.00 | -20B |
| Interest paid (cash effect) (JPY) | — | -7M | -35M | -38M | -48M | -52M | -68M | -387M | -717M | -997M |
| Operating cash flow before change in receivables (JPY) | — | 19.9B | 20.5B | 31B | 56.1B | 60.9B | 54B | 56.1B | 54.3B | 72.5B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | 14.1B | 16.4B | 23.9B | 44.6B | 48.9B | 49.5B | 50.7B | 42.8B | 58.3B |
| Income detail | ||||||||||
| Research and development expense (JPY) | — | — | 21M | 9M | 46M | — | — | — | — | — |
| Total comprehensive income (JPY) | — | 19.6B | 21.4B | 22.3B | 43.8B | 70.8B | 62.9B | 64.1B | 41.7B | 68.2B |
| Comprehensive income to owners (JPY) | 15B | 18.5B | 19.7B | 19.9B | 40.1B | 68.4B | 59.9B | 60.5B | 38.3B | 62.7B |
| Segments | ||||||||||
| Career Solution · Segment revenue (JPY) | — | 10.9B | 13.7B | 15.4B | 13.5B | 14.1B | 14.5B | 16.6B | 20.9B | 22.8B |
| ↳ YoY growth | +26.0% | +12.3% | -12.1% | +4.1% | +3.2% | +14.5% | +25.7% | +9.0% | ||
| Career Solution · Segment operating income (JPY) | — | 2.87B | 3.85B | 4.15B | 3.75B | 4.65B | 4.64B | 4.78B | 5.66B | 5.93B |
| Evidence Solution · Segment revenue (JPY) | — | 22.1B | 22.6B | 21.4B | 19.5B | 22.8B | 27.2B | 26.7B | 24.2B | 24.5B |
| ↳ YoY growth | +2.5% | -5.6% | -8.9% | +16.9% | +19.3% | -1.7% | -9.2% | +1.1% | ||
| Evidence Solution · Segment operating income (JPY) | — | 5.53B | 5.99B | 4.7B | 3.62B | 5.65B | 7.66B | 6.7B | 4.35B | 5.12B |
| Medical Platform · Segment revenue (JPY) | — | 34.3B | 41.2B | 51.3B | 77.1B | 85.9B | 93.1B | 93.4B | 91.6B | 108B |
| ↳ YoY growth | +20.2% | +24.3% | +50.3% | +11.5% | +8.3% | +0.3% | -2.0% | +17.8% | ||
| Medical Platform · Segment operating income (JPY) | — | 15.4B | 15.4B | 19.3B | 37.9B | 39.6B | 41.1B | 38.6B | 34.1B | 35.9B |
| Overseas · Segment revenue (JPY) | — | 22.4B | 25.1B | 30B | 42.1B | 51.8B | 62.1B | 69.9B | 80.6B | 86.9B |
| ↳ YoY growth | +12.0% | +19.3% | +40.7% | +23.0% | +19.8% | +12.5% | +15.3% | +7.9% | ||
| Overseas · Segment operating income (JPY) | — | 2.98B | 3.64B | 5.72B | 12.6B | 44.8B | 17B | 11.7B | 14.7B | 14.9B |
| Patient Solution · Segment revenue (JPY) | — | — | — | — | — | — | — | — | 21.9B | 56.9B |
| ↳ YoY growth | +159.5% | |||||||||
| Patient Solution · Segment operating income (JPY) | — | — | — | — | — | — | — | — | 824M | 2.69B |
| Site Solution · Segment revenue (JPY) | — | — | 9.18B | 12.2B | 16.6B | 35.2B | 35.3B | 33B | 47B | 54.4B |
| ↳ YoY growth | +33.1% | +35.4% | +112.5% | +0.3% | -6.4% | +42.4% | +15.5% | |||
| Site Solution · Segment operating income (JPY) | — | — | 881M | 944M | 1.54B | 3.4B | 3.75B | 3.74B | 5.42B | 5.77B |
| Reported | Jun 30, 2017 | Jun 28, 2019 | Jun 30, 2020 | Jun 30, 2020 | Jun 28, 2021 | Jun 29, 2023 | Jun 27, 2024 | Jun 27, 2024 | Jun 25, 2026 | Jun 25, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding M3, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| JAPN | 1.98% | 41,000 | $ 457.868K | Jun 30, 2026 |
| DFSI | 0.08% | 80,900 | $ 933.209K | Nov 12, 2026 |
| AVSD | 0.04% | 11,900 | $ 134.893K | Nov 16, 2026 |
| DFIC | 0.04% | 529,471 | $ 6.108M | Nov 12, 2026 |
| JSTC | 0.03% | 6,650 | $ 75.866K | Nov 17, 2026 |
| DFAX | 0.02% | 216,400 | $ 2.496M | Nov 12, 2026 |
| DFAI | 0.02% | 319,500 | $ 3.686M | Nov 12, 2026 |
| NTSI | 0.02% | 8,200 | $ 91.574K | Jun 30, 2026 |
| DXIV | 0.01% | 3,000 | $ 34.606K | Nov 12, 2026 |
| AVDE | 0.01% | 251,100 | $ 2.846M | Nov 16, 2026 |